Mode
Text Size
Log in / Sign up

Higher log GDP per capita is associated with higher Comprehensive Score for Financial ToxicityWealthier countries see higher costs for patients with cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that higher log GDP per capita is associated with higher COST scores, while high out-of-pocket costs worsen FT.

This meta-analysis evaluated the prevalence and predictors of financial toxicity (FT) among a large population of 83,623 adult patients with cancer. The analysis synthesized data from 75 COST-based studies conducted across 15 countries for the meta-analysis and 22 countries in total. The primary outcome measured was the Comprehensive Score for Financial Toxicity (COST), a validated tool used to quantify the impact of financial concerns on patient well-being.

The study specifically examined the relationship between country-level assets—including log GDP per capita, out-of-pocket health expenditure, population-level financial hardship, and vulnerable employment—and the resulting COST scores. The primary result indicated a pooled mean COST score of 21.2 (95% CI: 19.1-23.3; 95% prediction interval: 13.3-32.4). A variance decomposition of heterogeneity revealed that 46% of the observed heterogeneity was attributable to between-country differences, with GDP associations specifically explaining 43.1% of this between-country variance.

Regarding specific predictors, a positive association was found between log GDP per capita and COST scores (beta = 4.44; 95% CI: 2.90-5.98). This relationship remained robust even when sensitivity analyses excluded US-based studies. Conversely, the study identified several factors associated with worse financial toxicity outcomes, including higher out-of-pocket health expenditure, population-level financial hardship, and vulnerable employment.

While the meta-analysis provides a broad overview of global trends, it faces significant methodological limitations. The data exhibited substantial heterogeneity (I = 99.2%), which limits the standalone interpretability of the pooled mean COST score. Furthermore, the predominance of studies from the US (55%) may limit the ability to generalize findings across diverse healthcare systems without further context.

From a clinical and policy perspective, these results highlight the critical role that economic development strategies and investments in human capital play in safeguarding patients against population-level financial toxicity. The data suggest that while higher GDP is associated with higher COST scores, specific socioeconomic vulnerabilities like high out-of-pocket costs and precarious employment are significant drivers of patient distress. These findings underscore the need for systemic interventions to mitigate the economic burdens inherent in cancer treatment.

Several questions remain regarding the specific mechanisms by which these macro-economic factors translate into individual patient experiences. Additionally, more granular data on how different healthcare delivery models (e.g., universal vs. private) moderate the impact of GDP on financial toxicity are needed to inform targeted policy changes and clinical support systems.

How this fits prior evidence

How this fits prior evidence This meta-analysis addresses a gap in understanding the systemic and economic drivers of cancer patient experience. While previous findings have explored specific interventions like immersive virtual reality for anxiety or dexmethylphenidate for fatigue, this study provides new data on how macro-economic factors like log GDP per capita (beta = 4.44) and out-of-pocket expenditures impact the overall financial toxicity of cancer care.

When a person is diagnosed with cancer, the battle is not just physical. It is also financial. Many patients struggle to pay for treatments, medications, and daily needs while fighting their illness. This burden, known as financial toxicity, can cause immense stress and make it harder for people to focus on getting better. Understanding what causes these costs helps experts figure out how to protect patients from the heavy weight of medical bills.

To understand this issue on a global scale, researchers looked at data from over 83,000 cancer patients across many different countries. They used a specific tool called the COST score to measure financial toxicity. This score helps track how much the costs of treatment affect a patient's life and well-being. The study looked at various factors, including a country's wealth (measured by GDP), how much people pay out of their own pockets for healthcare, and how many people have unstable jobs.

The results showed a surprising link between a country's wealth and the cost to the patient. In fact, countries with higher levels of wealth actually saw higher scores for financial toxicity. This means that even in wealthier nations, cancer patients are still facing significant financial hurdles. The study also found that certain factors made things harder for individuals. Specifically, people who had to pay more out of their own pockets, lived in areas with high levels of financial hardship, or held unstable jobs faced worse financial outcomes.

It is important to look at these numbers with a careful eye. Because the data came from so many different countries and types of healthcare systems, there was a lot of variation in the results. Also, more than half of the studies included in this review were from the United States, which means the findings might not perfectly represent every country's unique situation. The high level of variety in the data makes it hard to say exactly how much any one factor contributes to a patient's experience.

What does this mean for patients today? It shows that financial stress is a global issue that does not disappear just because a country is wealthy. For healthcare providers and policymakers, these findings highlight the need for better support systems. By looking at where the biggest costs come from, they can work on ways to protect patients from financial hardship, regardless of where they live or how much money their country has.

What this means for you:
Wealthier countries still see high levels of financial toxicity in cancer care, highlighting a global need for support.

Study Details

Study typeMeta analysis
Sample sizen = 83,623
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Financial toxicity (FT), encompassing objective and subjective impacts of cancer care costs, is linked to poorer quality of life, reduced treatment adherence, and higher mortality. While patient-level risk factors have been examined, a system-level perspective incorporating socioeconomic context is needed to understand global variation in FT. METHODS: MEDLINE, CINAHL, Embase, and Web of Science were searched from inception to 06/27/2025 for peer-reviewed, English-language studies describing self-reported FT outcomes among adults with cancer. Reviewers extracted study characteristics, FT prevalence, predictors, and measurement tools. Financial, physical, and social asset measures from the World Bank were merged with FT data by study country and year of data collection. Focusing on studies reporting Comprehensive Score for Financial Toxicity (COST) scores, multilevel random effects meta-analysis was performed. Univariate and multivariate multilevel meta-regression evaluated relationships between country-level assets and COST. RESULTS: One hundred thirty-two studies from 22 countries were included, with FT prevalence ranging from 4.0% to 100.0%. Three-level meta-analysis of 75 COST-based studies (15 countries; 83,623 patients) yielded a pooled mean COST score of 21.2 (95% CI: 19.1-23.3; 95% prediction interval: 13.3-32.4), though substantial heterogeneity (I = 99.2%) and a predominance of studies from the US (55%) limited its standalone interpretability. Variance decomposition showed that 46% of heterogeneity was attributable to between-country differences. Higher log GDP per capita was associated with higher COST (β = 4.44, 95% CI: 2.90-5.98), explaining 43.1% of between-country variance. Higher out-of-pocket health expenditure, population-level financial hardship, and vulnerable employment were associated with worse FT. GDP associations were robust to sensitivity analyses excluding US-based studies. CONCLUSIONS: FT among cancer patients is linked to structural conditions governing access to education, employment, and financial systems, although expanded research in low-resource settings is needed. These findings highlight the roles of economic development strategies and investment in human capital in helping to safeguard against population-level FT.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.